A U.K. appeals court has rejected an attempt bid by Merck & Co. Inc. to revive a European patent covering Cosopt, paving the way for Teva UK Ltd. to push forth a generic version of the glaucoma treatment.
Merck & Co., is the second-biggest U.S. drug company. Teva UK is a subsidiary of Israel’s Teva Pharmaceutical Industries, the world’s biggest maker of generic drugs.
Teva sued Merck three years ago claims the patent shouldn’t have been granted after Merck filed the application in 1992. The Appeal upheld a November 2009 ruling that Merck’s patent lacked novelty or inventiveness was correct because experts in the field would have found the development to be obvious.
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Glaucoma is a disease of the optic nerve which receives light-generated nerve impulses from the retina and transmits these to the brain, where we recognize those electrical signals as vision.
Glaucoma is characterized by a particular pattern of progressive damage to the optic nerve that generally begins with a subtle loss of side vision (peripheral vision). If glaucoma is not diagnosed and treated, it can progress to loss of central vision and blindness.